The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
A new algorithm predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of five serum biomarkers.
 
Yuri Kogan
Employment - Optimata
Stock and Other Ownership Interests - Optimata
Travel, Accommodations, Expenses - Optimata
 
Marina Kleiman
Employment - Optimata
Stock and Other Ownership Interests - Optimata
 
Shmuel Shannon
Employment - Optimata
Stock and Other Ownership Interests - Optimata
 
Moran Elishmereni
Employment - Optimata
Stock and Other Ownership Interests - Optimata
 
Eldad Taub
Employment - Optimata
Leadership - Optimata
Stock and Other Ownership Interests - Optimata
Travel, Accommodations, Expenses - Optimata
 
Larisa Aptekar
No Relationships to Disclose
 
Ronen Mordechay Brenner
Consulting or Advisory Role - Merck Serono; Optimata
 
Raanan Berger
Stock and Other Ownership Interests - Belong; Mitra Biotech
Honoraria - AstraZeneca; Bristol-Myers Squibb; Mitra Biotech; MSD; Pfizer; Roche Israel
Consulting or Advisory Role - Belong; Mitra Biotech
Speakers' Bureau - Mitra Biotech
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Mitra Biotech; MSD
 
Hovav Nechushtan
No Relationships to Disclose
 
Zvia Agur
Employment - Optimata
Leadership - Optimata
Stock and Other Ownership Interests - Optimata
Travel, Accommodations, Expenses - Optimata